Another Dr Reddy’s Plant Runs Afoul Of German Regulator
Executive Summary
Dr Reddy’s Laboratories has suffered another blow, with a second manufacturing facility failing to pass muster with the German regulator. While the plant doesn’t currently make supplies to the EU, the firm’s recent run of compliance deviations threatens to erode investor confidence.
You may also be interested in...
Biocon, Dr Reddy’s Might Be Out Of The Woods On GMP Issue
Two Indian firms – Biocon and Dr Reddy’s – have received crucial establishment inspection reports (EIRs) from the US FDA amid improved compliance levels at their manufacturing sites.
Dr Reddy’s Faces US Class Action Case Heat
Pressure builds on Dr Reddy’s Laboratories after at least two US law firms press ahead with a class action case against the company. Analysts appear unperturbed, however – at least for now – about the possibility of any material implications.
Manufacturing Woes Continue To Plague Dr Reddy’s; Are Generic Gleevec Launch Plans Under Threat?
Dr Reddy’s Laboratories was battered on Indian bourses on March 9 after one of the firm’s formulation sites failed to get a clean chit from the FDA, piling up pressure on important US generic launch timelines.